Generalized anxiety disorders or general anxiety disorders (GAD) normally occurs alongside other mental or physical disorders such as substance or alcohol abuse that might cover the symptoms of anxiety. In some cases, these other disorders are treated before person’s response to a treatment for the disorder of anxiety. Well-organized remedies for normal disorders of anxiety are available, and current research is revealing ideal cures that may help many individuals suffering from GAD. In 2014, the demand from the U.S. for general anxiety disorder market was estimated at USD 3,251 Million. And by 2020, the same value is likely to generate USD 3,775 Million of revenue with a growth rate of 2.4% CAGR from 2015 to 2020.

General anxiety disorders market is flooded with different types of antidepressant medications that are accessible on prescription. General anxiety disorder market consists of various types of therapeutic segments such as benzodiazepines, antidepressant, and others. In 2014, the antidepressant was the important factor of the global market and covered 38.6% share of the total demand. Different types of medications are used to cure general anxiety disorder. Antidepressants such as selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) types are the initial line treatments.

Request Free Sample Report @

Benzodiazepine is the most widely used type of anti-anxiety drugs and normally used only for reducing major anxiety based on short-term. These are treatments eases anxiety by reducing the central nervous system down. Their relaxing and calming effects have made them well known in the U.S. They are also approved as sleeping pills and muscle relaxants.

In 2014, North America came up as the leading provincial market for the global depression. This was due to the occurrence of large population tainted with different types of anxiety and depression disorders. Some of the major players in this market include Sanofi S.A. Forest Laboratories, Inc., Eli Lilly, and Company, Merck & Co., Inc., Johnson & Johnson H. Lundbeck A/S, Pfizer, Inc., and others. In 2013, Eli Lilly and Company rolled out Duloxetine, a form of antidepressant that comes under the section of SNRIs, which are used to treat post-traumatic stress disorder, MDD, and general anxiety disorder (GAD).